Drugs /

yttrium y-90 ibritumomab tiuxetan

Back to Drugs List

Overview

NCI Definition [1]:
A radioimmunotherapeutic agent consisting of a murine monoclonal anti-CD20 antibody (ibritumomab) linked by the chelator tiuxetan to the radioisotope yttrium-90 (Y 90). Yttrium Y 90 ibritumomab tiuxetan binds to and specifically delivers beta radiation to CD20-expressing tumor cells, thereby minimizing the systemic effects of radiation.

Clinical Trials

View Clinical Trials for yttrium y-90 ibritumomab tiuxetan

Yttrium y-90 ibritumomab tiuxetan has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating yttrium y-90 ibritumomab tiuxetan, 1 is phase 2 (0 open) and 1 is phase 3 (1 open).

MS4A1 Expression is the most frequent biomarker inclusion criterion for yttrium y-90 ibritumomab tiuxetan clinical trials.

Burkitt lymphoma, diffuse large B-cell lymphoma, and mature B-cell lymphoma/leukemia are the most common diseases being investigated in yttrium y-90 ibritumomab tiuxetan clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Yttrium Y-90 Ibritumomab Tiuxetan
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Yttrium Y-90 Ibritumomab Tiuxetan
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating yttrium y-90 ibritumomab tiuxetan and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
10624, y90 zevalin, y90-labeled ibritumomab tiuxetan, ibritumomab (in2b8/y2b8 radiolabeling kit), y 90 zevalin, 710085, idec-y2b8 monoclonal antibody, yttrium y90 ibritumomab tiuxetan, y-90 ibitumomab tiuxetan, yttrium-90-ibritumomab tiuxetan, idec-y2b8, idec y2b8, yttrium y 90 ibritumomab tiuxetan, yttrium y-90 ibritumomab tiuxetan, y-90 ibritumomab tiuxetan, yttrium y 90 ibritumomab tiuxetan, 90y ibritumomab tiuxetan, yttrium-90 ibritumomab tiuxetan, 9462, y 90 ibritumomab tiuxetan, y 90 ibritumomab tiuxetan
Drug Target(s) [2]:
MS4A1
NCIT ID [1]:
C1812

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.